NCT00683891|Completed
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
FOCUS
Loading search results
FOCUS
Sponsor study identifier
observational
N/A
1 country
2
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedAZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or other atypical antipsychotics treatments. Another important clinical observation reported by doctors is a considerable reduction in hypersalivation when FazaClo administration is compared to other antipsychotic treatments. Based on the findings described above, and on the real need for effective and safer treatments for schizophrenia, AZUR Pharma has decided to design and conduct an observational study in a large number of patients taking FazaClo to prove the received clinical reports from physicians. Better understanding and evaluation of these beneficial findings are necessary to provide physicians information for improved treatment decision.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 22, 2008
Actual (reported)May 26, 2008
Actual (reported)Clinical changes in body weight in patients with treatment-resistant schizophrenia after initiating treatment with FazaClo
Clinical changes in salivation in patients with treatment-resistant schizophrenia after initiating treatment with FazaClo
Changes in Clinical Global Impression (CGI) scale when compared to baseline
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The enrolled population consists of male and female patients with treatment-resistant schizophrenia of 18 years of age or older, already taking Clozaril (clozapine) or generic clozapine, or patients with treatment-resistant schizophrenia who have failed on other atypical antipsychotic drugs.
Pacific Neuropsychiatric Specialists
Costa Mesa, California, 92626, United States
Gihwala & Associates
Gastonia, North Carolina, 28054, United States
First Submitted
May 22, 2008
First Posted
May 26, 2008
Last Updated
June 19, 2008
Record last verified: 2008-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Four Year Weight Change of Cornell Students
Contact the study team to confirm eligibility.